v3.24.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
|
| Total net revenue | $ 164,502 | $ 146,917 | $ 320,742 | $ 284,137 |
| COST OF REVENUE | 92,008 | 87,026 | 182,779 | 169,432 |
| GROSS PROFIT | 72,494 | 59,891 | 137,963 | 114,705 |
| Operating expenses: | ||||
| General and administrative | 63,328 | 60,308 | 129,125 | 121,857 |
| Research and development | 7,886 | 7,502 | 15,506 | 14,897 |
| Sales and marketing | 21,677 | 18,901 | 41,898 | 35,160 |
| Restructuring charges | 1,544 | 3,074 | 3,942 | 7,758 |
| Total operating expenses | 94,435 | 89,785 | 190,471 | 179,672 |
| LOSS FROM OPERATIONS | (21,941) | (29,894) | (52,508) | (64,967) |
| Interest income | (4,592) | (4,308) | (9,426) | (7,532) |
| Interest expense | 1,666 | 1,784 | 3,351 | 3,541 |
| Other expense (income), net | 2 | (730) | 265 | (616) |
| Loss before taxes | (19,017) | (26,640) | (46,698) | (60,360) |
| Income tax benefit | (375) | (2,309) | (995) | (5,234) |
| NET LOSS | $ (18,642) | $ (24,331) | $ (45,703) | $ (55,126) |
| NET LOSS PER SHARE | ||||
| Basic (in dollars per share) | $ (0.15) | $ (0.19) | $ (0.36) | $ (0.44) |
| Diluted (in dollars per share) | $ (0.15) | $ (0.19) | $ (0.36) | $ (0.44) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||
| Basic (in shares) | 126,405 | 125,356 | 126,257 | 125,192 |
| Diluted (in shares) | 126,405 | 125,356 | 126,257 | 125,192 |
| Clinical Services | ||||
| Total net revenue | $ 141,388 | $ 123,156 | $ 275,923 | $ 238,025 |
| COST OF REVENUE | 78,094 | 71,746 | 154,938 | 139,038 |
| GROSS PROFIT | 63,294 | 51,410 | 120,985 | 98,987 |
| Advanced Diagnostics | ||||
| Total net revenue | 23,114 | 23,761 | 44,819 | 46,112 |
| COST OF REVENUE | 13,914 | 15,280 | 27,841 | 30,394 |
| GROSS PROFIT | $ 9,200 | $ 8,481 | $ 16,978 | $ 15,718 |
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
